Original article
Vol. 141 No. 1112 (2011)
Hepatitis delta in Switzerland: a silent epidemic
Summary
OBJECTIVES:The sero-prevalence of co-infection with the hepatitis B virus (HBV) and the hepatitis D virus (HDV) is well known in many European countries, starting from 6.8% in Germany to more than 27% in some Turkish areas. To gain a better description of this infection in Switzerland, and to characterise those affected, a questionnaire was sent to all Swiss gastroenterologists, hepatologists and infectologists.
METHODS:A questionnaire was received by 349 physicians which asked them to report on all HBV- and HDV-infected patients seen at their units/offices.
RESULTS:A total of 101 HDV-positive patients seen by 78 specialists were analysed. The physicians were in charge of 1’699 patients with chronic hepatitis B, giving a 5.9% prevalence of HDV infection in HBV-positive patients. A predominance of males (75%) from Switzerland (39%), and of African origin (21%) was recorded. Most had been contaminated by intravenous drug use (62%), followed by vertical transmission (15%), sexual contact (13%) or transfusion with blood or blood products (2%). The majority (74%) had a very low (<103 UI/ml) HBV viral load and 75% were HBeAg-negative. A total of 76% percent of those who had a liver biopsy had significant fibrosis (≥F2), and only 21% had received standard therapy (interferon or pegylated interferon-α). Overall, 10% recovered spontaneously (anti-HBs-positive).
CONCLUSION:With a prevalence of 5.9% of hepatitis D in HBsAg-positive patients, Switzerland seems less affected than most other European countries, however, it is possible that this infection is under-diagnosed. Intravenous drug use was the main risk factor. Associated advanced liver disease was also very common.
References
- Rizzetto M, Canese MG, Arico S, Crivelli O, Bonino F, Trepo CG, et al. Immunofluorescence detection of a new antigen/antibody system (delta/anti-delta) associated with hepatitis B virus in liver and serum of HBsAg carriers. Gut. 1977;18:997–1003.
- Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian C, Thayer G, et al. Structure, sequence and expression of the hepatitis delta viral genome. Nature. 1986;323:508–14.
- Rizzetto M, Ponzetto A, Forzani I. Epidemiology of hepatitis delta virus: Overview. Prog Clin Biol Res. 1991;364:1.
- Hadziyannis SJ. Review: Hepatitis delta. J Gastroenterol Hepatol. 1997;12(4):289–98.
- Colombo P, et al. Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. J Hepatol. 1991;12:64–9.
- Aragona M, Macagno S, Caredda F, et al. Serological response to the hepatitis delta virus in hepatitis D. Lancet. 1987;1:478–82.
- Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Déni P, et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol. 2005;43:2363–9.
- Grabowski J, Wedemeyer H. Hepatitis Delta: Immunopathogenesis and clinical challenges. Dig Dis. 2010;28:133–8.
- Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology. 2000;32:824–7.
- Degertekin H, Yalçin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008;4:494–8.
- Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in central Europe. J Viral Hepat. 2009;16:883–94.
- Frösner GG, Franco E, Altorfer J, Decker RH, Mushahwar IK. Prevalence of Antibody to delta hepatitis virus population groups in west Germany and Switzerland. Eur J Clin Microbiol. 1985;4;147–9.
- Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection – not a vanishing disease in Europe. Hepatology. 2007;45:1331–2.
- Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31–40.
- Sheng W, Hung C, Kao J, Chang S, Chen M, Hsieh S, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active anti-retroviral therapy: a matched cohort study. Clin Infect Dis. 2007;44:988–95.
- Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43:100–7.
- Calle Serrano B, Heidrich B, Jaroszewicz J, Deterding K, Raupach R, Cornberg M, et al. Long-term outcome of hepatitis delta: A 14-year single center experience. Hepatology. 2009;50:737A.